The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Stephen Hanauer and David T. Rubin.
Connection Strength

5.561
  1. In memoriam. Inflamm Bowel Dis. 2012 Nov; 18(11):2001-3.
    View in: PubMed
    Score: 0.431
  2. Joseph Barnett Kirsner, MD, PhD. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1181-2.
    View in: PubMed
    Score: 0.431
  3. Joseph Barnett Kirsner, MD, PhD. Dig Dis Sci. 2012 Nov; 57(11):2722-4.
    View in: PubMed
    Score: 0.431
  4. Joseph Barnett Kirsner, MD, PhD. Gastrointest Endosc. 2012 Oct; 76(4):730-2.
    View in: PubMed
    Score: 0.429
  5. In memoriam: Dr Joseph Barnett Kirsner. Gut. 2012 Nov; 61(11):1636-7.
    View in: PubMed
    Score: 0.427
  6. Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes. Gastroenterol Hepatol (N Y). 2009 Jun; 5(6 Suppl):4-16.
    View in: PubMed
    Score: 0.340
  7. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun; 65(7):998-1004.
    View in: PubMed
    Score: 0.294
  8. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1346-50.
    View in: PubMed
    Score: 0.284
  9. Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. J Crohns Colitis. 2020 Oct 05; 14(10):1345-1353.
    View in: PubMed
    Score: 0.187
  10. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000 Aug; 12(8):855-62.
    View in: PubMed
    Score: 0.184
  11. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206.
    View in: PubMed
    Score: 0.158
  12. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
    View in: PubMed
    Score: 0.154
  13. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1557-1564.e1.
    View in: PubMed
    Score: 0.145
  14. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
    View in: PubMed
    Score: 0.140
  15. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
    View in: PubMed
    Score: 0.116
  16. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4.
    View in: PubMed
    Score: 0.113
  17. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
    View in: PubMed
    Score: 0.110
  18. Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7.
    View in: PubMed
    Score: 0.109
  19. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
    View in: PubMed
    Score: 0.102
  20. Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohns Colitis. 2012 Aug; 6(7):756-62.
    View in: PubMed
    Score: 0.102
  21. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci. 2012 Jan; 57(1):250-3.
    View in: PubMed
    Score: 0.101
  22. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.097
  23. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11.
    View in: PubMed
    Score: 0.094
  24. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010 Aug; 16(8):1352-6.
    View in: PubMed
    Score: 0.092
  25. Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):281-5; quiz 1 p following 285.
    View in: PubMed
    Score: 0.064
  26. Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):113-6; quiz 1 p following 116.
    View in: PubMed
    Score: 0.062
  27. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
    View in: PubMed
    Score: 0.053
  28. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
    View in: PubMed
    Score: 0.040
  29. miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling. Inflamm Bowel Dis. 2017 08; 23(8):1328-1337.
    View in: PubMed
    Score: 0.037
  30. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20.
    View in: PubMed
    Score: 0.035
  31. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
    View in: PubMed
    Score: 0.034
  32. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38.
    View in: PubMed
    Score: 0.033
  33. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
    View in: PubMed
    Score: 0.031
  34. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013 Mar; 19(3):662-8.
    View in: PubMed
    Score: 0.028
  35. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
    View in: PubMed
    Score: 0.027
  36. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis. 2012 Jan; 18(1):94-100.
    View in: PubMed
    Score: 0.024
  37. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.